Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527078) titled 'Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes' on April 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Gan & Lee Pharmaceuticals.

Condition: Type 2 Diabetes (T2DM)

Intervention: Drug: GZR33 Injection

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: April 7, 2026

Target Sample Size: 350

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07527078

Disclaimer: Curated b...